ÂÜÀòÂÒÂ×

Josh Barer's work experience includes serving as Chief Executive Officer of Hibiscus Capital Management since 2020, Co-Founder of Hibiscus BioVentures since 2019, Managing Partner of Barer & Son Capital since 2017, Director of AsclepiX Therapeutics since 2018, Venture Advisor of Israel Biotech Fund since 2015, Managing Director of Sunflower Life Sciences since 2016, Board Member of Family Promise, Inc since 2019, Executive Advisory Board Member and Graduate Fellow of the Center on Religion, Culture, and Conflict at Drew University since 2011, Board Member of Trickle Up since 2017, and Board Observer of NexImmune, Inc. since 2017.

Josh Barer began their educational journey in 2006 when they attended Rutgers University and earned a BA in Jewish Studies, Middle Eastern Literature and Languages in 2011. In 2008, they took part in a program at the University of Haifa in Middle Eastern Studies and also participated in the Credit Suisse YIO program. Josh then went on to attend Drew University from 2011 to 2013, where they studied Peace and Conflict Studies.